Adam M. Weidner

Array ( [id] => 12246257 [patent_doc_number] => 09919021 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-20 [patent_title] => 'Brain permeant peptidomimetic beta-secretase 1 inhibitors for the treatment or prophylaxis of neurological disorders or conditions' [patent_app_type] => utility [patent_app_number] => 15/099860 [patent_app_country] => US [patent_app_date] => 2016-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13260 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15099860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11455939 [patent_doc_number] => 20170049845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'METHODS OF TREATING ALZHEIMER\'S DISEASE, HUNTINGTON\'S DISEASE, AUTISM, OR OTHER DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/098985 [patent_app_country] => US [patent_app_date] => 2016-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6641 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15098985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421676 [patent_doc_number] => 20170029820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE I (DMI)' [patent_app_type] => utility [patent_app_number] => 15/094212 [patent_app_country] => US [patent_app_date] => 2016-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 22784 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15094212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15068497 [patent_doc_number] => 10463714 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-05 [patent_title] => Protoxin-II variants and methods of use [patent_app_type] => utility [patent_app_number] => 15/090328 [patent_app_country] => US [patent_app_date] => 2016-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 33075 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15090328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11798580 [patent_doc_number] => 09539298 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-10 [patent_title] => 'Lissencephaly therapeutic agent' [patent_app_type] => utility [patent_app_number] => 15/074142 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 34 [patent_no_of_words] => 33924 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15074142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12585045 [patent_doc_number] => 20180086844 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => ANTIBODIES AGAINST MAMMAL SECRETED KLOTHO PROTEIN [patent_app_type] => utility [patent_app_number] => 15/560096 [patent_app_country] => US [patent_app_date] => 2016-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15560096 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11409124 [patent_doc_number] => 09556417 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Reprogramming of cells to a new fate' [patent_app_type] => utility [patent_app_number] => 15/072769 [patent_app_country] => US [patent_app_date] => 2016-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 82 [patent_no_of_words] => 38794 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15072769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15132759 [patent_doc_number] => 10479826 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-19 [patent_title] => Single chain antibody domains for detection of anti-botulinum neurotoxin domains and methods of their use [patent_app_type] => utility [patent_app_number] => 15/553532 [patent_app_country] => US [patent_app_date] => 2016-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12611 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15553532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980017 [patent_doc_number] => 20160176961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'THROMBOPOIETIN RECEPTOR LIGANDS FOR NEUROPROTECTION' [patent_app_type] => utility [patent_app_number] => 15/054935 [patent_app_country] => US [patent_app_date] => 2016-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7202 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15054935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12205847 [patent_doc_number] => 20180051073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-22 [patent_title] => 'ANTI-TAU ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/552633 [patent_app_country] => US [patent_app_date] => 2016-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20608 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15552633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219192 [patent_doc_number] => 20180057551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'ALZHEIMER ABETA PEPTIDE BINDING POLYPEPTIDE' [patent_app_type] => utility [patent_app_number] => 15/548208 [patent_app_country] => US [patent_app_date] => 2016-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 35330 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15548208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15915377 [patent_doc_number] => 10654917 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-19 [patent_title] => Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders [patent_app_type] => utility [patent_app_number] => 15/545399 [patent_app_country] => US [patent_app_date] => 2016-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 46 [patent_no_of_words] => 42049 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15545399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12111844 [patent_doc_number] => 09867823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-16 [patent_title] => 'Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders' [patent_app_type] => utility [patent_app_number] => 15/004218 [patent_app_country] => US [patent_app_date] => 2016-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 75 [patent_no_of_words] => 42385 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15004218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13574723 [patent_doc_number] => 20180338910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => INTRANASAL ADMINISTRATION OF GLUTAMATE CARBOXYPEPTIDASE (GCP-II) INHIBITORS [patent_app_type] => utility [patent_app_number] => 15/542175 [patent_app_country] => US [patent_app_date] => 2016-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15542175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10776265 [patent_doc_number] => 20160122422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-05 [patent_title] => 'TREATMENT OF TAUOPATHIES' [patent_app_type] => utility [patent_app_number] => 14/989627 [patent_app_country] => US [patent_app_date] => 2016-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 41326 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14989627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436132 [patent_doc_number] => 20170037154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'COMPOSITION COMPRISING BRANCHED MULTIPEPTIDE VACCINE AND VACCINE COMPRISING THE SAME' [patent_app_type] => utility [patent_app_number] => 14/985660 [patent_app_country] => US [patent_app_date] => 2015-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 2426 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14985660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12219245 [patent_doc_number] => 20180057605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'BLOOD BRAIN BARRIER TRANSPORT MOLECULES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/536371 [patent_app_country] => US [patent_app_date] => 2015-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 25408 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15536371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13719949 [patent_doc_number] => 20170370929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => POSITIVE ALLOSTERIC MODULATORS OF THE DELTA-OPIOID RECEPTOR [patent_app_type] => utility [patent_app_number] => 15/535652 [patent_app_country] => US [patent_app_date] => 2015-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5326 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15535652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12199698 [patent_doc_number] => 09902754 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-27 [patent_title] => 'Modified peptides as potent inhibitors of the PSD-95/NMDA receptor interaction' [patent_app_type] => utility [patent_app_number] => 14/971432 [patent_app_country] => US [patent_app_date] => 2015-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 15 [patent_no_of_words] => 21260 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14971432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10754979 [patent_doc_number] => 20160101131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-14 [patent_title] => 'TREATMENT OF DISEASES' [patent_app_type] => utility [patent_app_number] => 14/968889 [patent_app_country] => US [patent_app_date] => 2015-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4555 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14968889 [rel_patent_id] =>[rel_patent_doc_number] =>)